Novel Spiro/non-Spiro Pyranopyrazoles: Eco-Friendly Synthesis, In-vitro Anticancer Activity, DNA Binding, and In-silico Docking Studies

Author(s): Paritosh Shukla* , Ashok Sharma , Leena Fageria , Rajdeep Chowdhury .

Journal Name: Current Bioactive Compounds

Volume 15 , Issue 2 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Cancer being a deadly disease, many reports of new chemical entities are available. Pyranopyrazole (PPZ) compounds have also been disclosed as bioactive molecules but mainly as antimicrobial agents. Based on one previous report and our interest in anticancer drug design, we decided to explore PPZs as anticancer agents. To the best of our knowledge, we found that a comprehensive study, involving synthesis, in-vitro biological activity determination, exploration of the mechanism of inhibition and finally in-silico docking studies, was missing in earlier reports. This is what the present study intends to accomplish.

Methods: Ten spiro and eleven non-spiro PPZ molecules were synthesized by environment-friendly multicomponent reaction (MCR) strategy. After subjecting each of the newly synthesized molecules to Hep3b hepatocellular carcinoma cell lines assay, we selectively measured the Optical Density (OD) of the most active ones. Then, the compound exhibiting the best activity was docked against human CHK- 1 protein to get an insight into the binding affinities and a quick structure activity relationship (SAR) of the PPZs.

Results: The two series of spiro and non-spiro PPZs were easily synthesized in high yields using microwave assisted synthesis and other methods. Among the synthesized compounds, most compounds showed moderate to good anticancer activity against the MTT assay. After performing the absorbance studies we found that the non-spiro molecules showed better apoptosis results and appeared to bind to DNA causing disruption in their structures. Finally, the docking results of compound 5h (having N,Ndimethylamino substituted moiety) clearly showed good binding affinities as predicted by our experimental findings.

Conclusion: The paper describes a comprehensive synthesis, in-vitro and docking studies done on new PPZs. The newly synthesized series of spiro and non-spiro PPZs were found to possess antineoplasmic activity as evinced by the studies on hep3b cells. Also, the UV visible absorbance study gave clues to the possible binding of these molecules to the DNA. Docking studies corroborated well with the experimental results. Thus, these new molecules appear to be potential anticancer agents, but further studies are required to substantiate and elaborate on these findings.

Keywords: Pyranopyrazoles, anticancer, microwave assisted, DNA binding, MTT assay, docking.

[2]
American Liver Foundation, USA Error! Hyperlink reference not valid.(Accessed February 22, 2017)..
[3]
Kim, I.; Song, J.H.; Park, C.M.; Jeong, J.W.; Kim, H.R.; Ha, J.R.; No, Z.; Hyun, Y-L.; Cho, Y.S.; Sook Kang, N.; Jeon, D.J. Design, synthesis, and evaluation of 2-aryl-7-(3′,4′-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidines as novel PDE-4 inhibitors. Bioorg. Med. Chem. Lett., 2010, 20(3), 922-926.
[4]
Devegowda, V.N.; Kim, J.H.; Han, K.C.; Yang, E.G.; Choo, H.; Pae, A.N.; Nam, G.; Choi, K.I. Novel 6-N-arylcarboxamidopyrazolo[4,3-d]pyrimidin-7-one derivatives as potential anti-cancer agents. Bioorg. Med. Chem. Lett., 2010, 20(5), 1630-1633.
[5]
Bakavoli, M.; Bagherzadeh, G.; Vaseghifar, M.; Shiri, A.; Pordel, M.; Mashreghi, M.; Pordeli, P.; Araghi, M. Molecular iodine promoted synthesis of new pyrazolo[3,4-d]pyrimidine derivatives as potential antibacterial agents. Eur. J. Med. Chem., 2010, 45(2), 647-650.
[6]
Ghorab, M.M.; Ragab, F.A.; Alqasoumi, S.I.; Alafeefy, A.M.; Aboulmagd, S.A. Synthesis of some new pyrazolo[3,4-d]pyrimidine derivatives of expected anticancer and radioprotective activity. Eur. J. Med. Chem., 2010, 45(1), 171-178.
[7]
Gilbert, A.M.; Nowak, P.; Brooijmans, N.; Bursavich, M.G.; Dehnhardt, C.; Santos, E.D.; Feldberg, L.R.; Hollander, I.; Kim, S.; Lombardi, S.; Park, K.; Venkatesan, A.M.; Mallon, R. Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-α: Hit to lead studies. Bioorg. Med. Chem. Lett., 2010, 20(2), 636-639.
[8]
Mousseau, J.J.; Fortier, A.; Charette, A.B. Synthesis of 2-substituted pyrazolo[1,5-a]pyridines through cascade direct alkenylation/cyclization reactions. Org. Lett., 2010, 12(3), 516-519.
[9]
Nascimento-Júnior, N.M.; Mendes, T.C.; Leal, D.M.; Corrêa, C.M.N.; Sudo, R.T.; Zapata-Sudo, G.; Barreiro, E.J.; Fraga, C.A. Microwave-assisted synthesis and structure-activity relationships of neuroactive pyrazolo[3,4-b]pyrrolo[3,4-d]pyridine derivatives. Bioorg. Med. Chem. Lett., 2010, 20(1), 74-77.
[10]
Wang, J.L.; Liu, D.; Zhang, Z-J.; Shan, S.; Han, X.; Srinivasula, S.M.; Croce, C.M.; Alnemri, E.S.; Huang, Z. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Natl. Acad. Sci. USA, 2000, 97(13), 7124-7129.
[11]
Zaki, M.; Morsy, E.; Abdel-Motti, F.; Abdel-Megeid, F. The Behaviour of Ethyl 1-acetyl-4-aryl-5-cyano-3-methyI-1, 4-dihydropyrano [2,3-c] pyrazol-6-ylimidoformate Towards Nucleophiles. Heterocycl. Commun., 2004, 10(1), 97-102.
[12]
Kidwai, M.; Saxena, S.; Khan, M.K.R.; Thukral, S.S. Aqua mediated synthesis of substituted 2-amino-4H-chromenes and in vitro study as antibacterial agents. Bioorg. Med. Chem. Lett., 2005, 15(19), 4295-4298.
[13]
Sharma, A.; Pallavi, B.; Singh, R.P. Novel grinding synthesis of pyranopyrazole analogues and their evaluation as antimicrobial agents. Heterocycles, 2015, 91(8), 1615-1627.
[14]
Foloppe, N.; Fisher, L.M.; Howes, R.; Potter, A.; Robertson, A.G.; Surgenor, A.E. Identification of chemically diverse Chk1 inhibitors by receptor-based virtual screening. Bioorg. Med. Chem., 2006, 14(14), 4792-4802.
[15]
Junek, H.; Aigner, H. Synthesen mit Nitrilen, XXXV. Reaktionen von tetracyanäthylen mit heterocyclen. Chem. Ber., 1973, 106(3), 914-921.
[16]
Arabanian, A.; Mohammadnejad, M.; Balalaie, S.; Gross, J.H. Synthesis of novel Gn-RH analogues using Ugi-4MCR. Bioorg. Med. Chem. Lett., 2009, 19(3), 887-890.
[17]
Rashinkar, G.; Salunkhe, R. Ferrocene labelled supported ionic liquid phase (SILP) containing organocatalytic anion for multi-component synthesis. J. Mol. Catal. Chem., 2010, 316(1), 146-152.
[18]
Shukla, P.; Sharma, A.; Anthal, S.; Kant, R. Synthesis of functionalized pyrazolopyran derivatives: comparison of two-step vs. one-step vs. microwave-assisted protocol and X-ray crystallographic analysis of 6-amino-1, 4-dihydro-3-methyl-4-phenylpyrano [2,3-c] pyrazole-5-carbonitrile. Bull. Mater. Sci., 2015, 38(5), 1119-1127.
[19]
Tacconi, G.; Gatti, G.; Desimoni, G.; Messori, V. A New Route to 4H‐Pyrano [2,3‐c] pyrazoles. J. Prakt. Chem., 1980, 322(5), 831-834.
[20]
Sharanina, L.G.; Marshtupa, V.; Sharanin, Y.A. Synthesis of 6‐amino‐5‐cyano‐1h, 4h‐pyrazolo [3,4‐b] pyrans. Khim. Geterotsikl. Soedin., 1981, 12(9), 1420-1424.
[21]
Sharanin, Y.A.; Shcherbina, L.; Sharanina, L.; Puzanova, V. nitrile cyclization reactions. vi. Synthesis of 2‐amino‐4‐(2‐furyl)‐4H‐pyrans. Zh. Org. Khim., 1983, 14(24), 164-173.
[22]
Sharma, A.; Chowdhury, R.; Dash, S.; Pallavi, B.; Shukla, P. Fast Microwave Assisted Synthesis of Pyranopyrazole Derivatives as New Anticancer Agents. Curr. Microw. Chem., 2016, 3(1), 78-84.
[23]
Pawar, P.B.; Jadhav, S.D.; Patil, B.M.; Shejwal, R.V.; Patil, S. Rapid one-pot four component synthesis of bioactive pyranopyrazoles using citric acid as a mild organocatalyst. Arch. Appl. Sci. Res., 2014, 6(1), 150-158.
[24]
Mecadon, H.; Rohman, M.R.; Rajbangshi, M.; Myrboh, B. γ-Alumina as a recyclable catalyst for the four-component synthesis of 6-amino-4-alkyl/aryl-3-methyl-2, 4-dihydropyrano [2,3-c] pyrazole-5-carbonitriles in aqueous medium. Tetrahedron Lett., 2011, 52(19), 2523-2525.
[25]
Vasuki, G.; Kumaravel, K. Rapid four-component reactions in water: synthesis of pyranopyrazoles. Tetrahedron Lett., 2008, 49(39), 5636-5638.
[26]
Kiyani, H.; Samimi, H.; Ghorbani, F.; Esmaieli, S. One-pot, four-component synthesis of pyrano [2,3-c] pyrazoles catalyzed by sodium benzoate in aqueous medium. Curr. Chem. Lett., 2013, 2(4), 197-206.
[27]
Fathy, M.A.; Nadia, H.M.; Sobhy, N.A. Synthesis and molluscicidal activity of some newly substituted Chromene and Pyrano[2,3-c]pyrazole derivatives. Afinidad. LXV, 2008, 538, 482-487.
[28]
Shestopalov, A.M.; Emeliyanova, Y.M.; Shestopalov, A.A.; Rodinovskaya, L.A.; Niazimbetova, Z.I.; Evans, D.H. One-step synthesis of substituted 6-amino-5-cyanospiro-4-(piperidine-4′)- 2H,4H-dihydropyrazolo[3,4-b]pyrans. Org. Lett., 2002, 4(3), 423-425.
[29]
Mandha, S.R.; Siliveri, S.; Alla, M.; Bommena, V.R.; Bommineni, M.R.; Balasubramanian, S. Eco-friendly synthesis and biological evaluation of substituted pyrano[2,3-c]pyrazoles. Bioorg. Med. Chem. Lett., 2012, 22(16), 5272-5278.
[30]
Mamaghani, M.; Nia, R.H.; Shirini, F.; Tabatabaeian, K.; Rassa, M. An efficient and eco-friendly synthesis and evaluation of antibactrial activity of pyrano [2,3-c] pyrazole derivatives. Med. Chem. Res., 2015, 24(5), 1916-1926.
[31]
Shestopalov, A.M.; Emeliyanova, Y.M.; Shestopalov, A.A.; Rodinovskaya, L.A.; Niazimbetova, Z.I.; Evans, D.H. Cross-condensation of derivatives of cyanoacetic acid and carbonyl compounds. Part 1: Single-stage synthesis of 1′-substituted 6-amino-spiro-4-(piperidine-4′)-2H, 4H-pyrano [2,3-c] pyrazole-5-carbonitriles. Tetrahedron, 2003, 59(38), 7491-7496.
[32]
Bihani, M.; Bora, P.P.; Bez, G.; Askari, H. Amberlyst A21 catalyzed chromatography-free method for multicomponent synthesis of dihydropyrano [2,3-c] pyrazoles in ethanol. ACS Sustain. Chem.& Eng., 2013, 1(4), 440-447.
[33]
Knasmüller, S.; Mersch-Sundermann, V.; Kevekordes, S.; Darroudi, F.; Huber, W.W.; Hoelzl, C.; Bichler, J.; Majer, B.J. Use of human-derived liver cell lines for the detection of environmental and dietary genotoxicants; current state of knowledge. Toxicology, 2004, 198(1-3), 315-328.
[34]
Li, Q.; Yang, P.; Wang, H.; Guo, M. Diorganotin(IV) antitumor agent. (C2H5)2SnCl2 (phen)/nucleotides aqueous and solid-state coordination chemistry and its DNA binding studies. J. Inorg. Biochem., 1996, 64(3), 181-195.
[35]
Penta, A.; Chander, S.; Ganguly, S.; Murugesan, S. De novo design and in-silico studies of novel 1-phenyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid derivatives as HIV-1 reverse transcriptase inhibitors. Med. Chem. Res., 2014, 23(8), 3662-3670.
[36]
Zhou, B.B.; Elledge, S.J. The DNA damage response: putting checkpoints in perspective. Nature, 2000, 408(6811), 433-439.
[37]
Senderowicz, A.M. The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01. Oncologist, 2002, 7(Suppl. 3), 12-19.
[38]
Foloppe, N.; Fisher, L.M.; Howes, R.; Kierstan, P.; Potter, A.; Robertson, A.G.; Surgenor, A.E. Structure-based design of novel Chk1 inhibitors: insights into hydrogen bonding and protein-ligand affinity. J. Med. Chem., 2005, 48(13), 4332-4345.
[39]
Ramtekkar, R.; Kandhasamy, K.; Vasuki, G.; Sekar, K.; Krishna, R. Computer-Aided Drug Design of Pyranopyrazoles and Related Compounds for Checkpoint Kinase-1. Lett. Drug Des. Discov., 2009, 6(8), 579-584.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 2
Year: 2019
Page: [257 - 267]
Pages: 11
DOI: 10.2174/1573407213666170828165512
Price: $58

Article Metrics

PDF: 19
HTML: 3
EPUB: 1
PRC: 1